RT Journal Article SR Electronic T1 Integrative genomics analysis implicates decreased FGD6 expression underlying risk of intracranial aneurysm rupture JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.03.12.22272299 DO 10.1101/2022.03.12.22272299 A1 Hale, Andrew T. A1 He, Jing A1 Jones, Jesse YR 2022 UL http://medrxiv.org/content/early/2022/03/14/2022.03.12.22272299.abstract AB Importance The genetic determinants and mechanisms underlying intracranial aneurysm rupture (rIA) are largely unknown. Given the ∼50% mortality rate of rIA, approaches to identify patients at high-risk will inform screening, diagnostic, and preventative measures.Objective To identify and characterize the genetic basis of rIA.Design We perform a genome-wide association study (GWAS) use functional genomics approaches to identify and characterize rIA-associated loci and genes.Setting We perform a meta-analysis across 24 published GWAS of rIA.Participants Our cohort contains 84,353 individuals (7,843 rIA cases and 76,510 controls).Main Outcome and Measure Single nucleotide polymorphisms (SNP), gene-burden analysis, and functional genomics identify and characterize genetic risk factors for rIA.Results We identify 5 independent genetic loci reaching genome-wide significance (p<5.0×10−8) for rIA including rs12310399 (FGD6, OR=1.16), which to our knowledge, has not been implicated in prior GWAS of (r)IA. We then quantified gene-level mutation-burden across ∼20,000 genes, and only FGD6 (containing 21 rIA-associated SNPs) reached transcriptome-wide significance. Expression quantitative trait loci (eQTL) mapping indicates that rs12310399 causes decreased FGD6 gene expression in arterial tissue. Single-cell RNA sequencing of normal human cerebrovascular cells obtained during resection surgery identified high expression of FGD6 in 1 of 3 arterial lineages but absent in perivascular cells. Patients with a Mendelian disease caused by FGD6 mutations (Aarskog-Scott syndrome) have been diagnosed with rIA, among other features, providing direct causal evidence for FGD6 in rIA pathogenesis.Conclusions and Relevance We identify and characterize a previously unknown risk loci for rIA containing FGD6. Variable expressivity of FDG6 causes a range of clinical features from Mendelian disease to sporadic rIA. Elucidation of high-risk genetic loci may instruct population-genetic screening and clinical-genetic testing strategies to identify patients predisposed to rIA.Funding No funding sources were used for the material presented herein.Question What are the genetic determinants of intracranial aneurysm rupture?Findings We identify FGD6 as a new risk locus for rIA using GWAS and gene-burden approaches. Characterization of the FGD6 locus and gene-level function using integrative genomics elucidates consequences of decreased FGD6 expression.Meaning Elucidating the genetic risk factors for rIA will instruct population-screening, genetic testing, and preventative measures aimed at reducing morbidity caused by rIA.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All genetic and functional genomics data were acquired through publicly available sources, where individual data-sharing policies and waivers of informed consent were obtained.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.